Europe To Review Validity Of Key Nexium Patent

Law360, New York (December 15, 2006, 12:00 AM EST) -- The European Patent Office plans to take a closer look at AstraZeneca PLC’s control of its blockbuster heartburn drug Nexium in an appeals case over the drug’s patent.

On Dec. 19, the patent office intends to review the pharmaceutical company’s patent, which was already affirmed in November 2003 after German generic drug maker Ratiopharm disputed the patent.

The EPO will consider whether Nexium’s patent is valid since the medication is actually a slightly revised form, or isomer, of another AstraZeneca blockbuster heartburn drug - Prilosec....
To view the full article, register now.